source
- Epicrispr secures $90M Series C to advance epigenetic therapy for rare muscle diseaseEpicrispr Biotechnologies announced a $90 million Series C financing round, led by Octagon Capital and Janus Henderson Investors, with participation from Sanofi Ventures and other investors. The c…
- Amgen to open new R&D Science and Innovation Center in Hyderabad's Genome Valley by 2027Amgen announced plans to establish a Science and Innovation Center in Hyderabad's Genome Valley, a biotech hub in India. The facility is slated to open in 2027 and will become part of Amgen's globa…